Sign in or create an account to add this stock to your watchlist.
About MabVax Therapeutics (NASDAQ:MBVX)
MabVax Therapeutics Holdings, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Its lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials. The company's product candidates include MVT-5873, a therapeutic antibody that is in Phase I clinical trial for patients with advanced or metastatic adenocarcinoma of the pancreas (PDAC) and other CA19-9 positive malignancies; and MVT-2163, an immuno-positron emission tomography (PET) imaging agent, which is in Phase I clinical trial designed to evaluate a next generation diagnostic PET imaging agent in patients with PDAC or other CA19-9 positive malignancies. Its product candidates also comprise MVT-1075, a radioimmunotherapy agent that combines the company's HuMab-5B1 antibody with the radiopharmaceutical (177) Lutetium to treat pancreatic cancer. The company has various research agreements and collaborations with Memorial Sloan Kettering Cancer Center; a licensing agreement with Life Technologies Corporation; a research collaboration agreement with Rockefeller University's Laboratory of Molecular Genetics and Immunology; and a development and manufacturing services agreement with Patheon. MabVax Therapeutics Holdings, Inc. was founded in 2006 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MBVX
CUSIPN/A
Phone858-259-9405
Debt
Debt-to-Equity Ratio1.48
Current Ratio0.21
Quick Ratio0.21
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$150,000.00
Price / Sales105.73
Cash FlowN/A
Price / CashN/A
Book Value$0.15 per share
Price / Book11.80
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-19,020,000.00
Net MarginsN/A
Return on Equity-2,767.01%
Return on Assets-199.42%
Miscellaneous
Employees11
Outstanding Shares8,960,000
MabVax Therapeutics (NASDAQ:MBVX) Frequently Asked Questions
What is MabVax Therapeutics' stock symbol?
MabVax Therapeutics trades on the NASDAQ under the ticker symbol "MBVX."
When did MabVax Therapeutics' stock split? How did MabVax Therapeutics' stock split work?
Shares of MabVax Therapeutics reverse split before market open on Friday, February 16th 2018. The 1-3 reverse split was announced on Thursday, February 15th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 15th 2018. An investor that had 100 shares of MabVax Therapeutics stock prior to the reverse split would have 33 shares after the split.
How were MabVax Therapeutics' earnings last quarter?
Who are some of MabVax Therapeutics' key competitors?
Some companies that are related to MabVax Therapeutics include KaloBios (HGEN), Oasmia Pharmaceutical (OASM), Acerus Pharmaceuticals (TRLPF), Helix Biopharma (HBPCF), Prima Biomed (IMMP), Novus Therapeutics (NVUS), vTv Therapeutics (VTVT), Versartis (VSAR), Alimera Sciences (ALIM), Zosano Pharma (ZSAN), Addex Pharmaceuticals (ADDXF), Evoke Pharma (EVOK), Celsion (CLSN), Imprimis Pharmaceuticals (IMMY) and ProPhase Labs (PRPH).
Who are MabVax Therapeutics' key executives?
MabVax Therapeutics' management team includes the folowing people:
- Mr. John David Hansen, Chairman, Pres & CEO (Age 67)
- Mr. Gregory P. Hanson C.M.A., M.B.A., MBA, CMA, CFO & Principal Accounting Officer (Age 71)
- Prof. Philip O. Livingston, Co-Founder, Chief Science Officer & Director (Age 75)
- Dr. Paul W. Maffuid, Exec. VP of R&D (Age 63)
- Dr. Paul F. Resnick, VP & Chief Bus. Officer (Age 61)
Has MabVax Therapeutics been receiving favorable news coverage?
Media coverage about MBVX stock has been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. MabVax Therapeutics earned a daily sentiment score of 0.06 on Accern's scale. They also assigned media headlines about the company an impact score of 47.11 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are MabVax Therapeutics' major shareholders?
MabVax Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Cambridge Investment Research Advisors Inc. (10.94%). Company insiders that own MabVax Therapeutics stock include Gregory P Hanson, John David Hansen, Paul F Resnick, Paul V Maier, Paul W Maffuid and Philip O Livingston. View Institutional Ownership Trends for MabVax Therapeutics.
Which institutional investors are buying MabVax Therapeutics stock?
How do I buy shares of MabVax Therapeutics?
Shares of MBVX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MabVax Therapeutics' stock price today?
One share of MBVX stock can currently be purchased for approximately $1.77.
How big of a company is MabVax Therapeutics?
MabVax Therapeutics has a market capitalization of $15.86 million and generates $150,000.00 in revenue each year. MabVax Therapeutics employs 11 workers across the globe.
How can I contact MabVax Therapeutics?
MabVax Therapeutics' mailing address is 11535 SORRENTO VALLEY ROAD SUITE 400, SAN DIEGO CA, 92121. The company can be reached via phone at 858-259-9405 or via email at [email protected]
MarketBeat Community Rating for MabVax Therapeutics (MBVX)
MarketBeat's community ratings are surveys of what our community members think about MabVax Therapeutics and other stocks. Vote "Outperform" if you believe MBVX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBVX will underperform the S&P 500 over the long term. You may vote once every thirty days.
MabVax Therapeutics (NASDAQ:MBVX) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
(Data available from 5/21/2016 forward)
MabVax Therapeutics (NASDAQ:MBVX) Earnings History and Estimates Chart
MabVax Therapeutics (NASDAQ MBVX) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | Q3 2017 | | ($1.62) | | | View | N/A |  |
| 8/14/2017 | Q2 2017 | ($2.07) | ($4.41) | | | View | N/A | |
| 5/24/2017 | Q1 2017 | ($2.43) | ($2.55) | | | View | N/A | |
| 3/1/2017 | Q4 2016 | | ($2.31) | | | View | N/A | |
| 11/7/2016 | Q3 2016 | ($2.22) | ($2.58) | | | View | N/A | |
| 8/11/2016 | Q2 2016 | ($4.23) | ($2.67) | | | View | N/A | |
| 5/9/2016 | Q1 2016 | ($3.54) | ($3.33) | $0.20 million | $0.15 million | View | N/A | |
| 10/30/2015 | Q3 2015 | | ($4.44) | | $0.13 million | View | N/A | |
| 8/10/2015 | Q2 2015 | ($2.67) | ($6.45) | $0.20 million | $0.14 million | View | N/A | |
| 5/15/2015 | Q1 2015 | | ($138.78) | | $0.24 million | View | N/A | |
| 5/15/2014 | Q1 2014 | | ($40.86) | | | View | N/A | |
| 3/10/2014 | Q4 2013 | | ($30.21) | | | View | N/A | |
| 11/12/2013 | Q3 2013 | | ($44.40) | | | View | N/A | |
| 8/9/2013 | Q2 2013 | | ($53.28) | | | View | N/A | |
| 5/10/2013 | Q1 2013 | | ($81.72) | | | View | N/A | |
| 3/15/2013 | Q4 2012 | | ($117.24) | | | View | N/A | |
| 11/9/2012 | Q312 | | ($2.34) | | | View | N/A | |
| 8/10/2012 | Q2 2012 | | ($197.19) | | | View | N/A | |
| 5/9/2012 | Q1 2012 | | ($222.78) | | | View | N/A | |
| 2/23/2012 | Q4 2011 | ($373.44) | ($245.40) | | | View | N/A | |
| 11/3/2011 | Q3 2011 | ($373.44) | ($282.75) | | | View | N/A | |
| 8/11/2011 | Q2 2011 | ($373.44) | ($320.07) | | | View | N/A | |
| 5/16/2011 | Q1 2011 | ($373.44) | ($373.44) | | | View | N/A | |
| 2/22/2011 | Q4 2010 | ($1,013.61) | ($400.11) | | | View | N/A | |
| 11/3/2010 | Q3 2010 | | ($464.13) | | | View | N/A | |
| 8/6/2010 | Q2 2010 | | ($496.14) | | | View | N/A | |
| 5/6/2010 | Q1 2010 | ($533.46) | ($533.46) | | | View | N/A | |
| 2/25/2010 | Q4 2009 | ($640.17) | ($426.78) | | | View | N/A | |
| 11/13/2009 | Q3 2009 | | ($586.83) | | | View | N/A | |
| 8/6/2009 | Q2 2009 | ($693.51) | ($565.47) | | | View | N/A | |
| 5/7/2009 | Q1 2009 | ($586.83) | ($773.52) | | | View | N/A | |
| 2/26/2009 | Q4 2008 | ($1,120.29) | ($37.35) | | | View | N/A | |
| 11/5/2008 | Q3 2008 | ($1,227.00) | ($736.20) | | | View | N/A | |
| 8/11/2008 | Q2 2008 | ($1,227.00) | ($1,360.35) | | | View | N/A | |
| 5/8/2008 | Q1 2008 | ($1,227.00) | ($986.91) | | | View | N/A | |
| 2/27/2008 | Q4 2007 | ($1,227.00) | ($1,307.01) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
MabVax Therapeutics (NASDAQ:MBVX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
MabVax Therapeutics (NASDAQ MBVX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 14.76%
Institutional Ownership Percentage: 35.91%
MabVax Therapeutics (NASDAQ MBVX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/24/2018 | Paul V Maier | Director | Sell | 35,448 | $0.85 | $30,130.80 | 96,351 | |
| 1/16/2018 | Gregory P Hanson | Insider | Sell | 41,873 | $0.92 | $38,523.16 | 320,013 | |
| 1/16/2018 | John David Hansen | CEO | Sell | 59,263 | $0.92 | $54,521.96 | 536,730 | |
| 1/16/2018 | Paul F Resnick | VP | Sell | 3,071 | $0.92 | $2,825.32 | 18,333 | |
| 1/16/2018 | Paul W Maffuid | EVP | Sell | 38,054 | $0.92 | $35,009.68 | 283,703 | |
| 1/12/2018 | Gregory P Hanson | CFO | Sell | 11,232 | $0.96 | $10,782.72 | 478,365 | |
| 1/12/2018 | John David Hansen | CEO | Sell | 18,582 | $0.96 | $17,838.72 | 788,683 | |
| 1/12/2018 | Paul F Resnick | VP | Sell | 824 | $0.96 | $791.04 | 29,944 | |
| 1/12/2018 | Paul W Maffuid | EVP | Sell | 10,207 | $0.96 | $9,798.72 | 427,608 | |
| 1/12/2018 | Philip O Livingston | Insider | Sell | 3,571 | $0.96 | $3,428.16 | 293,581 | |
| 1/10/2018 | Gregory P Hanson | CFO | Sell | 66,550 | $0.96 | $63,888.00 | 478,365 | |
| 1/10/2018 | John David Hansen | CEO | Sell | 110,093 | $0.96 | $105,689.28 | 788,683 | |
| 1/10/2018 | Paul F Resnick | VP | Sell | 4,879 | $0.96 | $4,683.84 | 29,944 | |
| 1/10/2018 | Paul W Maffuid | EVP | Sell | 60,478 | $0.96 | $58,058.88 | 427,608 | |
| 1/10/2018 | Philip O Livingston | Insider | Sell | 21,155 | $0.96 | $20,308.80 | 293,581 | |
| 4/12/2017 | John David Hansen | Insider | Sell | 10,216 | $2.00 | $20,432.00 | 61,473 | |
| 4/11/2017 | John David Hansen | Insider | Sell | 1,476 | $2.00 | $2,952.00 | 72,499 | |
| 4/6/2017 | John David Hansen | Insider | Sell | 5,051 | $2.17 | $10,960.67 | 77,116 | |
| 3/24/2016 | Jeffrey V. Ravetch | Director | Sell | 131,500 | $0.60 | $78,900.00 | | |
| 5/29/2015 | Paul V Maier | Director | Buy | 5,000 | $2.30 | $11,500.00 | | |
| 5/22/2015 | Kenneth M Cohen | Director | Buy | 3,500 | $2.30 | $8,050.00 | | |
| 12/17/2014 | Kenneth M Cohen | Director | Buy | 2,500 | $1.80 | $4,500.00 | | |
| 12/16/2014 | Gregory P Hanson | CFO | Buy | 3,000 | $2.50 | $7,500.00 | | |
| 12/16/2014 | Robert Hoffman | Director | Buy | 10,000 | $2.40 | $24,000.00 | | |
| 9/12/2014 | Jim J Antonopoulos | Director | Sell | 11,892 | $6.00 | $71,352.00 | | |
(Data available from 1/1/2013 forward)
MabVax Therapeutics (NASDAQ MBVX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | MabVax Therapeutics Receives U.S. Patent for Fully Human Antibodies Targeting the Antigen GD2 Expressed on Sarcoma, Melanoma, and Neuroblastoma
finance.yahoo.com - May 17 at 9:55 AM |
| MabVax Therapeutics Presentation from VirtualInvestorConferences.com Now Available for On-Demand Viewing
finance.yahoo.com - May 7 at 9:29 AM |
 | MabVax Therapeutics (MBVX) Announces Private Placement Offering
www.streetinsider.com - May 3 at 4:15 PM |
| MabVax Therapeutics Holdings, Inc. Announces Private Placement Offering
finance.yahoo.com - May 3 at 4:15 PM |
 | MabVax Therapeutics (MBVX) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - May 3 at 12:10 AM |
| MabVax Therapeutics Antibody Program Results Featured in Three Presentations at 2018 American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 18 at 9:41 AM |
 | MabVax receives listing deficiency notice from Nasdaq
seekingalpha.com - April 14 at 9:51 AM |
| MabVax Therapeutics (MBVX) Receives Continued Listing Deficiency Notice from Nasdaq
www.streetinsider.com - April 14 at 9:51 AM |
| MabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaq's Minimum Stockholders' Equity Requirements
finance.yahoo.com - April 13 at 4:18 PM |
| Form 8-K MABVAX THERAPEUTICS HOLD For: Apr 02
www.streetinsider.com - April 3 at 10:00 AM |
 | MabVax Therapeutics Reports 2017 Operational and Financial Results and 2018 Milestones
www.prnewswire.com - April 2 at 8:08 AM |
| Why MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) Ownership Structure Is Important
finance.yahoo.com - March 22 at 4:13 PM |
| MabVax Therapeutics (MBVX) Announces Acceptance of Three Poster Presentations at AACR
www.streetinsider.com - March 16 at 10:01 AM |
| MabVax Therapeutics Announces Acceptance of Three Poster Presentations at the 2018 American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - March 15 at 9:36 AM |
| With A -68.72% Earnings Drop, Did MabVax Therapeutics Holdings Inc (NASDAQ:MBVX) Really Underperform?
finance.yahoo.com - March 14 at 10:45 AM |
| MabVax Therapeutics (MBVX) Regains Compliance with NASDAQ's $1.00 Minimum Bid Price
www.streetinsider.com - March 6 at 4:39 PM |
| MabVax Therapeutics Regains Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement
finance.yahoo.com - March 6 at 9:33 AM |
| Short Interest in MabVax Therapeutics Holdings, Inc. (MBVX) Declines By 39.2%
www.americanbankingnews.com - March 4 at 1:40 AM |
| MabVax up 22% premarket on early-stage MVT-1075 data
seekingalpha.com - March 1 at 4:39 PM |
| MabVax Therapeutics Reports Positive Safety Results from Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers
finance.yahoo.com - February 28 at 9:36 AM |
| MabVax Therapeutics (MBVX) says 1-for-3 reverse stock split is scheduled to be effective with opening of trading on Friday, February 16
www.streetinsider.com - February 15 at 4:25 PM |
 | BRIEF-MabVax Therapeutics Says Reverse Stock Split Is Scheduled To Be Effective With Opening Of Trading On Feb 16
www.reuters.com - February 15 at 8:54 AM |
| MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement
finance.yahoo.com - February 15 at 8:54 AM |
| MabVax Therapeutics (MBVX) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 14 at 9:01 AM |
| MabVax Therapeutics Announces Positive Interim Data from Expanded Cohort in Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy in Pancreatic Cancer
finance.yahoo.com - February 12 at 8:57 AM |
| INVESTOR NOTICE: The Schall Law Firm Announces the Investigation of Securities Claims Against MabVax Therapeutic Holdings, Inc. - MBVX
finance.yahoo.com - February 8 at 4:31 PM |
| MabVax to Present at BIO CEO & Investor Conference
finance.yahoo.com - February 7 at 9:03 AM |
| MabVax Therapeutics Closes $2.1 Million Private Placement Financing
finance.yahoo.com - February 6 at 8:59 AM |
| MabVax Therapeutics (MBVX) Lifted to Sell at ValuEngine
www.americanbankingnews.com - February 4 at 10:48 PM |
| IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Investigation of Securities Claims Against MabVax Therapeutic Holdings, Inc. - MBVX
finance.yahoo.com - January 31 at 4:39 PM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MabVax Therapeutics Holdings, Inc. (MBVX)
www.prnewswire.com - January 31 at 1:43 PM |
| EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against MabVax Therapeutics Holdings, Inc. – MBVX
finance.yahoo.com - January 31 at 9:13 AM |
| All You Need To Know About MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) Risks
finance.yahoo.com - January 31 at 9:13 AM |
| MabVax Receives Notice of SEC Investigation and Examination of Certain Registration Statements
finance.yahoo.com - January 30 at 9:22 AM |
| MabVax Therapeutics Holdings, Inc. (MBVX) Director Sells $30,130.80 in Stock
www.americanbankingnews.com - January 24 at 9:24 PM |
| How Should Investors Feel About MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) CEO Pay?
finance.yahoo.com - January 23 at 4:14 PM |
| Gregory P. Hanson Sells 41,873 Shares of MabVax Therapeutics Holdings, Inc. (MBVX) Stock
www.americanbankingnews.com - January 18 at 9:58 PM |
| Paul W. Maffuid Sells 38,054 Shares of MabVax Therapeutics Holdings, Inc. (MBVX) Stock
www.americanbankingnews.com - January 18 at 9:58 PM |
| Insider Selling: MabVax Therapeutics Holdings, Inc. (MBVX) CEO Sells 59,263 Shares of Stock
www.americanbankingnews.com - January 18 at 9:58 PM |
| MabVax Therapeutics Holdings, Inc. Provides Business Strategy Update
finance.yahoo.com - January 16 at 9:19 AM |
| MabVax Therapeutics Holdings, Inc. (MBVX) Insider Sells $20,308.80 in Stock
www.americanbankingnews.com - January 16 at 6:24 AM |
| MabVax Therapeutics Holdings, Inc. (MBVX) CFO Sells $10,782.72 in Stock
www.americanbankingnews.com - January 16 at 6:24 AM |
| MabVax Therapeutics Holdings, Inc. (MBVX) EVP Sells $58,058.88 in Stock
www.americanbankingnews.com - January 16 at 6:24 AM |
| Insider Selling: MabVax Therapeutics Holdings, Inc. (MBVX) CEO Sells 18,582 Shares of Stock
www.americanbankingnews.com - January 16 at 6:24 AM |
| John David Hansen Sells 110,093 Shares of MabVax Therapeutics Holdings, Inc. (MBVX) Stock
www.americanbankingnews.com - January 16 at 6:24 AM |
| Insider Selling: MabVax Therapeutics Holdings, Inc. (MBVX) CFO Sells 66,550 Shares of Stock
www.americanbankingnews.com - January 16 at 6:24 AM |
| Is MabVax Therapeutics Holdings Inc (NASDAQ:MBVX) On The Right Side Of Disruption?
finance.yahoo.com - January 4 at 4:56 PM |
| Wired News – MabVax Therapeutics Completes Enrollment and Initial Patient Dosing in Expanded Cohort of the Phase-1 Trial Evaluating MVT-5873
finance.yahoo.com - December 22 at 9:22 AM |
| BRIEF-MabVax Therapeutics Says Completed Patient Enrollment In Expanded Cohort Of Phase-1 Trial Testing MVT-5873
www.reuters.com - December 20 at 4:52 PM |
| BRIEF-MabVax Therapeutics Files For Resale Of 16.6 Mln Shares Of Co's Common Stock
www.reuters.com - December 15 at 9:31 AM |
MabVax Therapeutics (NASDAQ:MBVX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
MabVax Therapeutics (NASDAQ:MBVX) Income Statement, Balance Sheet and Cash Flow Statement
MabVax Therapeutics (NASDAQ MBVX) Stock Chart for Monday, May, 21, 2018
Loading chart…
